RSS-Feed abonnieren
DOI: 10.1055/s-0044-1785485
Reviewing the Rich History of Fibrin Clot Research with a Focus on Clinical Relevance
Funding This work was supported by the Jagiellonian University Medical College (N/41/DBS/001040 to A.U.).![](https://www.thieme-connect.de/media/sth/202405/lookinside/thumbnails/10-1055-s-0044-1785485_03214-1.jpg)
Abstract
Fibrin, described on a single-lens microscopy for the first time by Malpighi in 1666 and named by de Fourcroy, has been extensively studied by biochemists, biophysicists, and more recently by clinicians who recognized that fibrin is the major component of most thrombi. Elucidation of key reactions leading to fibrin clot formation in the 1950s and 1960s grew interest in the clinical relevance of altered fibrin characteristics. Implementation of scanning electron microscopy to image fibrin clots in 1947 and clot permeation studies in the 1970s to evaluate an average pore size enabled plasma clot characterization in cohorts of patients. Unfavorably altered fibrin clot structure was demonstrated by Blombäck's group in coronary artery disease in 1992 and in diabetes in 1996. Fifteen years ago, similar plasma fibrin clot alterations were reported in patients following venous thromboembolism. Multiple myeloma was the first malignant disease to be found to lead to abnormal fibrin clot phenotype in the 1970s. Apart from anticoagulant agents, in 1998, aspirin was first shown to increase fibrin clot permeability in cardiovascular patients. The current review presents key data on the rich history of fibrin research, in particular, those that first documented abnormal fibrin clot properties in a variety of human disease states, as well as factors affecting fibrin phenotype.
Publikationsverlauf
Artikel online veröffentlicht:
11. April 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Litvinov RI, Weisel JW. What is the biological and clinical relevance of fibrin?. Semin Thromb Hemost 2016; 42 (04) 333-343
- 2 Litvinov RI, Pieters M, de Lange-Loots Z, Weisel JW. Fibrinogen and fibrin. Subcell Biochem 2021; 96: 471-501
- 3 Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost 2023; 21 (11) 3005-3015
- 4 Forrester JM. Malpighi's De polypo cordis: an annotated translation. Med Hist 1995; 39 (04) 477-492
- 5 Weisel JW, Litvinov RI. Visualizing thrombosis to improve thrombus resolution. Res Pract Thromb Haemost 2021; 5 (01) 38-50
- 6 Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 2016; 22 (02) 109-114
- 7 Rosenfeld L. The fibrinogen to fibrin transformation. In: Origins of Clinical Chemistry: The Evolution of Protein Analysis. New York, NY:: Academic Press;; 1982: 366
- 8 Owen Jr CA. A History of Blood Coagulation. Mayo Foundation for Medical Education and Research.; 2001
- 9 Mihalyi E. Electrophoretic investigation of fibrin and fibrinogen dissolved in urea solutions. Acta Chem Scand 1950; 4: 351-358
- 10 Laki K. The polymerization of proteins; the action of thrombin on fibrinogen. Arch Biochem Biophys 1951; 32 (02) 317-324
- 11 Lorand L. A study on the solubility of fibrin clots in urea. Hung Acta Physiol 1948; 1 (06) 192-196
- 12 Bailey K, Bettelheim FR, Lorand L, Middlebrook WR. Action of thrombin in the clotting of fibrinogen. Nature 1951; 167 (4241) 233-234
- 13 Lorand L. Fibrino-peptide. Biochem J 1952; 52: 200-203
- 14 Ferry JD. The mechanism of polymerization of fibrin. Proc Natl Acad Sci U S A 1952; 38 (07) 566-569
- 15 Hermans J, McDonagh J. Fibrin: structure and interactions. Semin Thromb Hemost 1982; 8 (01) 11-24
- 16 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229
- 17 Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29 (03) 177-188
- 18 Hall CE. Electron microscopy of fibrinogen and fibrin. J Biol Chem 1949; 179 (02) 857-864
- 19 Hantgan RR, Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem 1979; 254 (22) 11272-11281
- 20 Weisel JW, Nagaswami C, Makowski L. Twisting of fibrin fibers limits their radial growth. Proc Natl Acad Sci U S A 1987; 84 (24) 8991-8995
- 21 Drake B, Prater CB, Weisenhorn AL. et al. Imaging crystals, polymers, and processes in water with the atomic force microscope. Science 1989; 243 (4898) 1586-1589
- 22 Roberts WW, Lorand L, Mockros LF. Viscoelastic properties of fibrin clots. Biorheology 1973; 10 (01) 29-42
- 23 Gerth C, Roberts WW, Ferry JD. Rheology of fibrin clots. II. Linear viscoelastic behavior in shear creep. Biophys Chem 1974; 2 (03) 208-217
- 24 Guthold M, Liu W, Stephens B. et al. Visualization and mechanical manipulations of individual fibrin fibers suggest that fiber cross section has fractal dimension 1.3. Biophys J 2004; 87 (06) 4226-4236
- 25 Liu W, Jawerth LM, Sparks EA. et al. Fibrin fibers have extraordinary extensibility and elasticity. Science 2006; 313 (5787) 634
- 26 Brown AEX, Litvinov RI, Discher DE, Purohit PK, Weisel JW. Multiscale mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water. Science 2009; 325 (5941) 741-744
- 27 Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008; 111 (10) 4854-4861
- 28 He S, Wallén H, Thålin C, Svensson J, Blombäck M. Fibrin network porosity and endo-/exogenous thrombin cross-talk. Semin Thromb Hemost 2021; 47 (07) 775-786
- 29 Van Zandt Hawn C, Porter KR. The fine structure of clots formed from purified bovine fibrinogen and thrombin: a study with the electron microscope. J Exp Med 1947; 86 (04) 285-292
- 30 Ferry JD, Morrison PR. Preparation and properties of serum and plasma proteins; the conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 1947; 69 (02) 388-400
- 31 Ferry JD. Protein gels. Adv Protein Chem 1948; 4: 1-78
- 32 Signer R, Egli H. Sedimentation von Makromolekülen und Durchströmung von Gelen. Rec Trav Chim 1950; 69: 45-58
- 33 Carr Jr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16 (01) 1-15
- 34 Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25 (1-2): 51-70
- 35 Okada M, Blombäck B. Factors influencing fibrin gel structure studied by flow measurement. Ann N Y Acad Sci 1983; 408: 233-253
- 36 Carr ME. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 1988; 59 (03) 535-539
- 37 Galanakis DK, Lane BP, Simon SR. Albumin modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with fibrinogen. Biochemistry 1987; 26 (08) 2389-2400
- 38 Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983; 101 (04) 545-552
- 39 Carr ME, White II GC, Gabriel DA. Platelet factor 4 enhances fibrin fiber polymerization. Thromb Res 1987; 45 (05) 539-543
- 40 Bale MD, Westrick LG, Mosher DF. Incorporation of thrombospondin into fibrin clots. J Biol Chem 1985; 260 (12) 7502-7508
- 41 Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75 (05) 521-538
- 42 Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; 101 (08) 3008-3013
- 43 Pieters M, Undas A, Marchi R, De Maat MP, Weisel J, Ariëns RA. Factor XIII And Fibrinogen Subcommittee Of The Scientific Standardisation Committee Of The International Society For Thrombosis And Haemostasis. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost 2012; 10 (10) 2179-2181
- 44 Wolberg AS, Sang Y. Fibrinogen and factor XIII in venous thrombosis and thrombus stability. Arterioscler Thromb Vasc Biol 2022; 42 (08) 931-941
- 45 Mills JD, Ariëns RAS, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106 (15) 1938-1942
- 46 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
- 47 Dunn EJ, Ariëns RA, de Lange M. et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103 (05) 1735-1740
- 48 Williams FM, Carter AM, Kato B. et al; EuroCLOT Investigators. Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2009; 29 (04) 600-605
- 49 Standeven KF, Uitte de Willige S, Carter AM, Grant PJ. Heritability of clot formation. Semin Thromb Hemost 2009; 35 (05) 458-467
- 50 Casini A, Duval C, Pan X, Tintillier V, Biron-Andreani C, Ariëns RAS. Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thromb Res 2016; 137: 189-195
- 51 Mammen EF, Prasad AS, Barnhart MI, Au CC. Congenital dysfibrinogenemia: fibrinogen Detroit. J Clin Invest 1969; 48 (02) 235-249
- 52 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
- 53 Collet JP, Soria J, Mirshahi M. et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82 (08) 2462-2469
- 54 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-186
- 55 Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014; 12 (10) 1687-1696
- 56 Carlisle CR, Sparks EA, Der Loughian C, Guthold M. Strength and failure of fibrin fiber branchpoints. J Thromb Haemost 2010; 8 (05) 1135-1138
- 57 Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96 (03) 988-995
- 58 Ajjan R, Lim BC, Standeven KF. et al. Common variation in the C-terminal region of the fibrinogen β-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008; 111 (02) 643-650
- 59 Lim BC, Ariëns RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361 (9367) 1424-1431
- 60 Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107 (18) 2326-2330
- 61 Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102 (02) 535-540
- 62 Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68 (02) 130-135
- 63 Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997 (1-2): 96-110
- 64 Bini A, Fenoglio Jr JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989; 9 (01) 109-121
- 65 Chernysh IN, Nagaswami C, Kosolapova S. et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep 2020; 10 (01) 5112
- 66 Silvain J, Collet J-P, Nagaswami C. et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57 (12) 1359-1367
- 67 Williams S, Fatah K, Hjemdahl P, Blombäck M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 1998; 19 (11) 1666-1672
- 68 Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost 2019; 45 (04) 413-422
- 69 Litvinov RI, Nabiullina RM, Zubairova LD, Shakurova MA, Andrianova IA, Weisel JW. Lytic susceptibility, structure, and mechanical properties of fibrin in systemic lupus erythematosus. Front Immunol 2019; 10: 1626
- 70 Wygrecka M, Birnhuber A, Seeliger B. et al. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. Blood Adv 2022; 6 (03) 1074-1087
- 71 Undas A, Szułdrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196 (02) 551-557
- 72 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125 (04) 357-361
- 73 Undas A, Podolec P, Zawilska K. et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 2009; 40 (04) 1499-1501
- 74 Martinez MR, Cuker A, Mills AM. et al. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. Am J Physiol Lung Cell Mol Physiol 2014; 306 (05) L397-L404
- 75 Jörneskog G, Egberg N, Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39 (12) 1519-1523
- 76 Colle JP, Mishal Z, Lesty C. et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency?. Thromb Haemost 1999; 82 (05) 1482-1489
- 77 Lackner H, Hunt V, Zucker MB, Pearson J. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol 1970; 18 (06) 625-636
- 78 Sjøland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98 (02) 339-345
- 79 Undas A, Topór-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost 2009; 102 (06) 1289-1291
- 80 Rajzer M, Wojciechowska W, Kawecka-Jaszcz K, Undas A. Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. Thromb Res 2012; 130 (01) 99-103
- 81 Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76 (04) 535-540
- 82 Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006; 4 (05) 973-975
- 83 Standeven KF, Ariëns RAS, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002; 51 (01) 189-197
- 84 Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4 (05) 1029-1036
- 85 Jörneskog G, Hansson L-O, Wallen NH, Yngen M, Blombäck M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1 (06) 1195-1201
- 86 Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011; 31 (07) 1696-1702
- 87 Ząbczyk M, Majewski J, Karkowski G, Malinowski KP, Undas A. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation. Thromb Res 2015; 136 (04) 832-838
- 88 He S, Blombäck M, Bark N, Johnsson H, Wallén NH. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost 2010; 103 (05) 1076-1084